Dear Fellow Investor, On December 13, 2022, a Big Pharma giant quietly bought one AI-designed drug for $4 billion. That makes it the biggest deal for an AI-designed drug in history. But very few people even know about it...yet.
| | Even leading investors in the U.S. have no idea. And they don't know that this tiny AI-biotech designed the drug. But this won't stay quiet much longer. On January 9, 2023, ristol Myers Squibb signed a $2.7 billion deal to have their AI-platform develop six new drugs. On October 6, 2022, Eli Lilly signed a $425 million deal to have their AI-platform develop a new drug. These seven drugs alone could bring $28 billion to this little-known company. That doesn't include deals they signed with Sanofi, Nimbus Therapeutics, Petra Pharma and others. Wall Street doesn't yet grasp how this company is quietly revolutionizing the drug discovery business... Which is why I believe this will be the biggest AI winner you never heard of. Get the name of the stock here...while it's still a small-cap >>> "The Buck Stops Here," | |
| |
E-mail Letter | A special message from the Editor of Volatility Indicators: We are often approached by other businesses with special offers for our readers. While many don’t make the cut, the message above is one we believe deserves your consideration. |
|
|
| | | This email was sent to you by Volatility Indicators on behalf of Event Horizon LLC. If you need personalized assistance or have questions, please respond to this email for a swift response. Contact [email protected] for other inquiries. Copyright © 2024 All Rights Reserved. 435 N Dupont Hwy, Dover, DE 19901, United States Terms & Conditions | Privacy Policy | Unsubscribe |
|
|
|
|
| |
|
|
|